In recent years, a number of large placebo-controlled outcome studies have demonstrated that treatment with SGLT2 inhibitors versus placebo leads to a lower risk of kidney outcomes and progression of kidney disease. The gene discussed is SLC5A2; the disease is kidney disorder.